黏膜相关恒定T细胞在结核病合并糖尿病患者中的数量和功能变化

doi:10.3760/cma.j.cn441417-20240904-01015

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (1): 70-74.DOI: 10.3760/cma.j.cn441417-20240904-01015

黏膜相关恒定T细胞在结核病合并糖尿病患者中的数量和功能变化

梁建嫦¹ 吴永坚²

¹广东药科大学附属第二医院云浮市中医院检验科，云浮 527300；²中山大学附属第五医院感染与免疫学研究中心，珠海 519000

收稿日期:2024-09-04 出版日期:2025-01-01 发布日期:2025-01-14
通讯作者: 吴永坚，Email：wuyj228@mail.sysu.edu.cn
基金资助:
广东省自然科学基金（2023A1515030065）

Quantitative and functional alterations in mucosal-associated invariant T cells in tuberculosis patients with concurrent diabetes mellitus

Liang Jianchang¹, Wu Yongjian²

¹Department of Laboratory Medicine, The Second Affiliated Hospital of Guangdong Pharmaceutical University, Yunfu Hospital of Traditional Chinese Medicine, Yunfu 527300, China; ²Center for Infection and Immunity, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, China

Received:2024-09-04 Online:2025-01-01 Published:2025-01-14
Contact: Wu Yongjian, Email: wuyj228@mail.sysu.edu.cn
Supported by:
Natural Science Foundation of Guangdong Province (2023A1515030065)

摘要/Abstract

摘要：

目的　探讨初治涂阳肺结核合并糖尿病患者外周血黏膜相关恒定T（MAIT）细胞的数量和功能变化。方法　本研究为横断面研究。选取2022年10月至2023年10月在中山大学附属第五医院就诊的61例结核病患者为研究对象，根据结核病患者是否合并糖尿病分为肺结核合并糖尿病（PTB+DM）组及单纯肺结核（PTB）组。PTB组患者30例中男25例，女5例，年龄（33.14±8.76）岁。PTB+DM组患者31例中男22例，女9例，年龄（31.57±9.56）岁。检测两组患者的外周血MAIT细胞比例、MAIT细胞经牛分枝杆菌（BCG）感染后的活化标志CD69和细胞因子干扰素-γ（IFN-γ）表达变化。统计学方法采用t检验。结果　PTB+DM组患者外周血MAIT细胞比例低于PTB组［（1.04±0.13）%比（1.79±0.25）%］，差异有统计学意义（t=2.727，P=0.008）；PTB+DM组CD4+、CD8+T细胞比例分别为（22.91±1.77）%、（7.91±1.05）%，PTB组分别为（27.30±1.34）%、（10.47±1.41）%，差异均无统计学意义（t=1.971、1.469，均P>0.05）。PTB+DM组MAIT细胞经BCG感染后CD69表达和IFN-γ分泌水平均低于PTB组［（5.88±0.71）%比（9.04±1.08）%、（13.82±1.66）%比（26.06±3.77）%］，差异均有统计学意义（均P<0.05）。结论　肺结核合并糖尿病患者外周血MAIT细胞数量减少，且活化和分泌细胞因子的能力明显下降。

关键词:

结核病, 糖尿病, 黏膜相关恒定T细胞

Abstract:

Objective　To investigate changes in the quantity and function of peripheral blood mucosal-associated invariant T (MAIT) cells in newly diagnosed smear-positive pulmonary tuberculosis (PTB) patients with diabetes mellitus (DM). Methods　This was a cross-sectional study.A total of 61 PTB patients treated in the Fifth Affiliated Hospital of Sun Yat-sen University from October 2022 to October 2023 were selected as the study objects. According to whether the PTB patients were combined with DM, they were divided into a PTB+DM group and a PTB group. Among the 30 patients in the PTB group, there were 25 males and 5 females, aged (33.14±8.76) years. Among the 31 patients in the PTB+DM group, there were 22 males and 9 females, aged (31.57±9.56) years. The proportion of MAIT cells in peripheral blood, the activation marker CD69 and cytokine interferon-γ (IFN-γ) expressions of MAIT cells after infected with Mycobacterium bovis BCG were detected in the two groups. t test was used for statistical analysis. Results　The proportion of MAIT cells in peripheral blood of the PTB+DM group was lower than that of the PTB group [(1.04±0.13)% vs. (1.79±0.25)%], with a statistically significant difference (t=2.727, P=0.008). The proportions of CD4+ and CD8+T cells were (22.91±1.77)% and (7.91±1.05)% in the PTB+DM group, and (27.30±1.34)% and (10.47±1.41)% in the PTB group, without statistically significant difference (t=1.971 and 1.469, both P>0.05). The expression levels of CD69 and IFN-γ in MAIT cells after infection in the PTB+DM group were lower than those in the PTB group [(5.88±0.71)% vs. (9.04±1.08)%, (13.82±1.66)% vs. (26.06±3.77)%], with statistically significant differences (both P<0.05). Conclusions　Peripheral blood MAIT cell numbers are reduced in PTB patients with concurrent DM, and their activation and cytokine secretion capacity are significantly impaired.

Key words:

Tuberculosis, Diabetes mellitus, Mucosal-associated invariant T cells

梁建嫦吴永坚.

黏膜相关恒定T细胞在结核病合并糖尿病患者中的数量和功能变化 [J]. 国际医药卫生导报, 2025, 31(1): 70-74.

Liang Jianchang, Wu Yongjian.

Quantitative and functional alterations in mucosal-associated invariant T cells in tuberculosis patients with concurrent diabetes mellitus [J]. International Medicine and Health Guidance News, 2025, 31(1): 70-74.

参考文献

[1] 邓国防. «结核病与糖尿病共病的治疗管理专家共识»解读[J]. 中国防痨杂志,2021,43(4):318-321. DOI:10.3969/j.issn.1000-6621.2021.04.004.
[2] 龚兰,许婉华,谢贝,等. 肺结核患者治疗过程中血清IFN-γ表达水平变化分析[J]. 国际医药卫生导报,2023,29(10):1343-1348. DOI:10.3760/cma.j.issn.1007-1245.2023. 10.003.
[3] Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2·3 million patients with tuberculosis[J]. Lancet Glob Health, 2019, 7(4): e448-e460. DOI: 10.1016/S2214-109X(18)30487-X.
[4] Restrepo BI. Diabetes and tuberculosis[J]. Microbiol Spectr, 2016, 4(6):10.1128/microbiolspec.TNMI7-0023-2016. DOI: 10.1128/microbiolspec.TNMI7- 0023-2016.
[5] Boadu AA, Yeboah-Manu M, Osei-Wusu S, et al. Tuberculosis and diabetes mellitus: the complexity of the comorbid interactions[J]. Int J Infect Dis, 2024, 146:107140. DOI: 10.1016/j.ijid.2024.107140.
[6] Godfrey DI, Koay HF, McCluskey J, et al. The biology and functional importance of MAIT cells[J]. Nat Immunol, 2019, 20(9): 1110-1128. DOI: 10.1038/s41590-019- 0444-8.
[7] Provine NM, Klenerman P. MAIT cells in health and disease[J]. Annu Rev Immunol, 2020, 38: 203-228. DOI: 10.1146/annurev-immunol-080719-015428.
[8] 曹志红,程小星. 黏膜相关恒定T细胞在抗结核分枝杆菌免疫中的作用[J]. 中华结核和呼吸杂志,2023,46(5):511-516. DOI:10.3760/cma.j.cn112147-20230307-00117.
[9] 国家感染性疾病临床医学研究中心,深圳市第三人民医院,国家代谢性疾病临床医学研究中心,等. 结核病与糖尿病共病的治疗管理专家共识[J]. 中国防痨杂志,2021,43(1):12-22. DOI:10.3969/j.issn.1000-6621.2021.01.004.
[10] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)(上)[J]. 中国实用内科杂志,2021,41(8):668-695. DOI:10.19538/j.nk2021080106.
[11] Li X, Wang M, Ming S, et al. TARM-1 is critical for macrophage activation and th1 response in mycobacterium tuberculosis infection[J]. J Immunol, 2021, 207(1): 234-243. DOI: 10.4049/jimmunol.2001037.
[12] Ming S, Zhang M, Liang Z, et al. OX40L/OX40 signal promotes IL-9 production by mucosal MAIT cells during helicobacter pylori infection[J]. Front Immunol, 2021, 12:626017. DOI: 10.3389/fimmu.2021.626017.
[13] 张艺. 肺结核合并糖尿病临床特点分析[J]. 国际检验医学杂志,2016,37(12):1667-1669. DOI:10.3969/j.issn.1673- 4130.2016.12.027.
[14] 李烨,叶晓光,李进. 肺结核合并2型糖尿病56例临床分析[J]. 国际医药卫生导报,2010,16(16):1969-1971. DOI:10.3760/cma.j.issn.1007-1245.2010.16.013.
[15] Kumar Nathella P, Babu S. Influence of diabetes mellitus on immunity to human tuberculosis[J]. Immunology, 2017, 152(1): 13-24. DOI: 10.1111/imm.12762.
[16] Chengalroyen MD. Current perspectives and challenges of MAIT cell-directed therapy for tuberculosis infection[J]. Pathogens, 2023, 12(11): 1343. DOI: 10.3390/pathogens12111343.
[17] Corbett AJ, Eckle SB, Birkinshaw RW, et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways[J]. Nature, 2014, 509(7500): 361-365. DOI: 10.1038/nature13160.
[18] Bucsan AN, Rout N, Foreman TW, et al. Mucosal-activated invariant T cells do not exhibit significant lung recruitment and proliferation profiles in macaques in response to infection with mycobacterium tuberculosis CDC1551[J]. Tuberculosis (Edinb), 2019, 116S: S11-S18. DOI: 10.1016/j.tube.2019.04.006.
[19] Sakai S, Lora NE, Kauffman KD, et al. Functional inactivation of pulmonary MAIT cells following 5-OP-RU treatment of non-human primates[J]. Mucosal Immunol, 2021, 14(5): 1055-1066. DOI: 10.1038/s41385-021- 00425-3.
[20] Le Bourhis L, Martin E, Péguillet I, et al. Antimicrobial activity of mucosal-associated invariant T cells[J]. Nat Immunol, 2010, 11(8): 701-708. DOI: 10.1038/ni.1890.
[21] Jiang J, Wang X, An H, et al. Mucosal-associated invariant T-cell function is modulated by programmed death-1 signaling in patients with active tuberculosis[J]. Am J Respir Crit Care Med, 2014, 190(3):329-339. DOI: 10.1164/rccm.201401-0106OC.
[22] Jiang J, Cao Z, Qu J, et al. PD-1-expressing MAIT cells from patients with tuberculosis exhibit elevated production of CXCL13[J]. Scand J Immunol, 2020, 91(4): e12858. DOI: 10.1111/sji.12858.
[23] Jiang J, Yang B, An H, et al. Mucosal-associated invariant T cells from patients with tuberculosis exhibit impaired immune response[J]. J Infect, 2016, 72(3): 338-352. DOI: 10.1016/j.jinf.2015.11.010.
[24] Rouxel O, Da Silva J, Beaudoin L, et al. Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes[J]. Nat Immunol, 2017, 18(12):1321-1331. DOI: 10.1038/ni.3854.
[25] Endesfelder D, zu Castell W, Ardissone A, et al. Compromised gut microbiota networks in children with anti-islet cell autoimmunity[J]. Diabetes, 2014, 63(6): 2006-2014. DOI: 10.2337/db13-1676.
[26] Zhang M, Ming S, Gong S, et al. Activation-induced cell death of mucosal-associated invariant T cells is amplified by OX40 in type 2 diabetic patients[J]. J Immunol, 2019, 203(10): 2614-2620. DOI: 10.4049/jimmunol.1900367.
[27] O'Brien A, Loftus RM, Pisarska MM, et al. Obesity reduces mTORC1 activity in mucosal-associated invariant T cells, driving defective metabolic and functional responses[J]. J Immunol, 2019, 202(12): 3404-3411. DOI: 10.4049/jimmunol.1801600.
[28] Bertrand L, Lehuen A. MAIT cells in metabolic diseases[J]. Mol Metab, 2019, 27S Suppl:S114-S121. DOI: 10.1016/j.molmet.2019.06.025.
[29] Magalhaes I, Kiaf B, Lehuen A. iNKT and MAIT cell alterations in diabetes[J]. Front Immunol, 2015, 6:341. DOI: 10.3389/fimmu.2015.00341.

黏膜相关恒定T细胞在结核病合并糖尿病患者中的数量和功能变化

Quantitative and functional alterations in mucosal-associated invariant T cells in tuberculosis patients with concurrent diabetes mellitus

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	董璐莹王越淇黄晓程王佳. 沉默lncRNA Gm9866表达对高糖诱导的胰岛β细胞损伤的保护作用[J]. 国际医药卫生导报, 2025, 31(2): 177-182.
[2]	邢文华梁栋刘洁李梦洁张晓敏. 线粒体动力学在糖尿病肾病中的作用及调节机制 [J]. 国际医药卫生导报, 2025, 31(2): 183-187.
[3]	朱白雪党江波周美娇. IDegLira联合七叶皂苷钠片治疗糖尿病视网膜病变合并黄斑水肿患者的效果 [J]. 国际医药卫生导报, 2025, 31(2): 187-192.
[4]	杨文娟吕倩倩王杰刘晓宁强薇边芳. 探讨血清Perilipin-2联合尿Netrin-4预测2型糖尿病患者糖尿病肾病的临床价值 [J]. 国际医药卫生导报, 2025, 31(2): 193-197.
[5]	王荣荣张进. 三一照护管理模式对2型糖尿病患者血糖、自我管理水平及生活质量的影响 [J]. 国际医药卫生导报, 2025, 31(2): 198-202.
[6]	郭浩楠吴红群. 益气通络方对2型糖尿病患者疗效的影响 [J]. 国际医药卫生导报, 2025, 31(2): 203-208.
[7]	郭志梅王明明. 多学科协作下路径护理对老年糖尿病肾病维持性血液透析肌少症患者的效果 [J]. 国际医药卫生导报, 2025, 31(2): 208-213.
[8]	宋佰慧. 糖尿病性胃轻瘫大鼠胃平滑肌组织连接蛋白43的动态变化及意义 [J]. 国际医药卫生导报, 2025, 31(1): 51-54.
[9]	马利军刘占军韩继明. miR-150-5p、miR-135b在糖尿病肾病患者中的表达及意义 [J]. 国际医药卫生导报, 2024, 30(9): 1454-1459.
[10]	谢丽月郑智慧杨银锦叶秀玉卢亚聪. 专科化游戏对学龄期1型糖尿病患儿负性情绪及自我效能的影响 [J]. 国际医药卫生导报, 2024, 30(9): 1579-1584.
[11]	邹皓珍杨佳席哲帆纪瑞董华. 单细胞RNA测序技术在肾病中的研究进展 [J]. 国际医药卫生导报, 2024, 30(8): 1307-1311.
[12]	王满华张韬张永刚. 化瘀复明汤联合羟苯磺酸钙治疗糖尿病视网膜病变患者的疗效观察 [J]. 国际医药卫生导报, 2024, 30(7): 1136-1141.
[13]	刘睿茜杨阳高金祥. 应用托伐普坦治疗糖尿病肾病综合征所致顽固性水肿个案分析 [J]. 国际医药卫生导报, 2024, 30(7): 1172-1176.
[14]	高琳琳隋赟王立新. 二甲双胍治疗2型糖尿病患者发生胃肠道不良反应的风险因素分析 [J]. 国际医药卫生导报, 2024, 30(7): 1176-1181.
[15]	于娜杨娜娜吴敏张迪梅. 病房-门诊-家庭模式对糖尿病视网膜病变患者延续性护理的影响 [J]. 国际医药卫生导报, 2024, 30(7): 1211-1217.